Kuhn W et al. (8)
|
37
|
Better median survival in the group treated with neoadjuvant chemotherapy compared with the group treated with primary cytoreductive surgery
|
Onnis A et al. (9)
|
88
|
In 46% of operated patients, the residual tumour was < 2 cm. An improvement in the quality of surgery and disease-free period was observed, while survival rate did not improve when comparing the neoadjuvant chemotherapy group to the group that received adjuvant chemotherapy
|
Shimizu Y et al. (10)
|
74
|
In 46% of operated patients, the residual tumour was < 2 cm. Survival for the optimally debulked neoadjuvant chemotherapy group was significantly higher than that for the optimally debulked adjuvant chemotherapy group
|
Vergote I et al. (11)
|
75
|
Crude survival was higher when selecting about one-half of patients for neoadjuvant chemotherapy
|
Surwit E. et al. (12)
|
29
|
Median survival was 22 months
|
Schwartz PE et al. (13)
|
59
|
No statistical difference was observed in overall and progression-free survival between the group treated with neoadjuvant chemotherapy and the conventionally treated group
|
Jacob JH et al. (14)
|
22
|
The same survival as in 18 matched controls
|
Lim JT et al. (15)
|
30
|
Neoadjuvant chemotherapy can make patients operable
|
Lawton FG et al. (16)
|
36
|
78% of patients were treated with neoadjuvant chemotherapy, of whom in 89% the residual tumour was < 2 cm
|
Ansquer Y et al. (17)
|
54
|
Better survival of patients treated with neoadjuvant chemotherapy compared to patients with non-debulked tumours
|
Recchia F et al. (18)
|
34
|
Median survival was 28 months for stage IV patients
|
Loizzi V et al. (19)
|
30
|
Survival in the neoadjuvant and adjuvant chemotherapy groups was similar
|
Kayikcioglu F et al. (20)
|
45
|
Primary neoadjuvant chemotherapy followed by cytoreductive surgery did not appear to worsen the prognosis
|
Morice P et al. (21)
|
57
|
Survival rates were similar in patients who underwent interval debulking surgery or primary debulking surgery
|
Ivanov S et al. (22)
|
46
|
The five-year survival rate following the neoadjuvant chemotherapy was the same as in case of conventional chemotherapy
|